+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 19Years +
All Genders
ID07123415

Phase 1 Trial of APX-343A Alone or with Pembrolizumab to Evaluate Safety and Preliminary Effects in Advanced Solid Tumors

Led by Aptabio Therapeutics, Inc. · Updated on 2026-10-09

110

Participants Needed

3

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a Phase 1, open-label study to evaluate the safety, tolerability, pharmacokinetics, and initial effectiveness of APX-343A alone and in combination with pembrolizumab in adults with advanced solid tumors. This study aims to better understand how these treatments behave in the body and their potential effects in this patient group. The study has two parts Part A tests increasing doses of APX-343A by itself, while Part B tests increasing doses of APX-343A together with pembrolizumab. APX-343A is given orally twice daily, and pembrolizumab is administered intravenously. Participants receive the assigned treatment to assess safety and determine appropriate doses. Participants will be monitored from enrollment through 90 days after treatment ends to evaluate safety and tolerability. Researchers will also measure drug levels in the body during the first three weeks and assess tumor response over about one year. The study involves regular assessments including tumor biopsies, imaging, and health status evaluations to track outcomes and effects.

CONDITIONS

Brief Title

A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Research Team

C

Clinical Center, Clinical Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here